Nexalin's device administers a frequency-based waveform that is designed to treat patients in a pain-free and undetectable manner. The Gen-2 and Gen-3 stimulation techniques rely on strategically ...
On Thursday, Nexalin Technology, Inc (NASDAQ:NXL) (NASDAQ:NXLIW) announced results from a clinical trial of its Deep Intracranial Frequency Stimulation (DIFS) technology for mild Alzheimer’s disease.
How can we ensure that life-saving drugs or genetic therapies reach their intended target cells without causing harmful side effects? Researchers at Helmholtz Munich, Ludwig-Maximilians-Universität ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results